Transgene Biotek has entered into a definitive licensing and technology transfer agreement with Atral Cipan of Portugal. The agreement provides the basis for the manufacture, commercialization and marketing of the immune-suppressant drug Tacrolimus using technology developed and transferred by Transgene Biotek. As a result of this agreement, Atral Cipan will move the product through regulatory filings with the US FDA and European Medicines Agency (EMEA) for the manufacturing and marketing of Tacrolimus.